

PANCREATIC DISEASE ORIENTED GROUP

CHELSEA HOTEL, TORONTO, ON
 ROOM: ROSSETTI
 SATURDAY APRIL 28, 2018, 10:45 AM – 11:45 AM (1 HOUR)

CO-CHAIRS : DR. DAN RENOUF AND DR. ALICE WEI
 SENIOR INVESTIGATOR: DR. CHRIS O'CALLAGHAN

CME Credits:

Credits for Specialists: This event is an Accredited Group Learning Activity (Section 1) as defined by the Maintenance of Certification program of the Royal College of Physicians and Surgeons of Canada, and approved by Queen's University.

Learning Objectives:

- *To interpret and address, through clinical and translational research, the disease burden associated with pancreatic malignancies in Canada.*
- *To summarize recent developments in the understanding of molecular biology and therapeutics as these relate to pancreatic malignancies.*
- *To cite and analyze recent results of clinical studies conducted by or in collaboration with the Canadian Cancer Trials Group relevant to pancreatic malignancies.*
- *To interpret and apply new clinical trial methodologies in the field of clinical research in pancreatic malignancies.*

10:45 am	Setting Strategic Plan	Dr. D. Renouf
	Active/Recently Closed Trials for Update	
11:05 am	PA.6 (ACCORD 24): Randomized Multicenter Phase III Comparison of Adjuvant Chemotherapy with Gemcitabine versus a Combination of 5-Fluorouracil, Leucovorin, Irinotecan And Oxaliplatin (mFOLFIRINOX) in Patients with Resected Pancreatic Adenocarcinoma	Dr. J. Biagi
11:10 am	PA.7: A Randomized Phase II Trial of Gemcitabine and Nab-Paclitaxel vs. Gemcitabine, Nab-Paclitaxel, Durvalumab and Tremelimumab as 1st Line Therapy in Metastatic Pancreatic Adenocarcinoma	Dr. D. Renouf
11:20 am	New Concepts in Development Neoadjuvant FOLFIRINOX Trial concept	Dr. G. O'Kane
11:35 am	COMPASS/PANGEN Sequencing Update	Dr. D. Renouf
11:40 am	Intergroup Task Force Update	Dr. D. Renouf
11:45 am	Meeting Adjourned	